TILS.L Regulatory News (TILS)

10 Mar 2008 07:00

ReGen Therapeutics PLC10 March 2008 For immediate release 10 March 2008 ReGen Appoints Golgi Pharmaceuticals Ltd of Cyprus as first European-basedDistributor for ColostrininTM ReGen Therapeutics Plc ('ReGen'or the 'Company') is pleased to announce that ithas today signed the first European distribution agreement for its nutritionalsupplement ColostrininTM with Golgi Pharmaceuticals Ltd of Cyprus.* This deal isconditional on Golgi being able to secure importation approval for the productfrom the Cypriot authorities, which it has now applied for. To dateColostrininTM is marketed in the US and Australian markets under the brand nameCogniSureTM as a nutritional supplement to 'support healthy brain aging andcognition in humans'** Commenting on the first agreement signed in the European Union Percy Lomax,Chairman and Chief Executive Officer of ReGen said : 'Cyprus is a relatively small market in its own right but it is a member of theEuropean Union which, with the US and Japan, is one of the three key targetareas for ColostrininTM. This launch is into the professional and retail channeland this allows distribution in all health food stores and pharmacies'. * Golgi Pharmaceuticals Ltd is a distributor of pharmaceuticals andnutraceuticals in the Republic of Cyprus. (email address of GolgiPharmaceuticals Ltd - golgipha@cytanet.com.cy) **ColostrininTM for use as a human nutraceutical is licensed in North Americaand Australasia to Metagenics Inc. of San Clemente, California (www.Metagenics.com). Discussions are ongoing with potential distributors inother regions of the world. For further information: Percy LomaxReGen Therapeutics PlcTel No 020 7153 4920 Roland Cornish/Felicity GeidtBeaumont Cornish LimitedTel No 020 7628 3396 This information is provided by RNS The company news service from the London Stock Exchange